Pricing
  1. JP-listed companies
  2. K Pharma,Inc.
  3. Financials
  4. Net income

K Pharma,Inc.【JP:4896】

Market cap
¥9.2B
P/E ratio
-13.4x
K Pharma develops treatments for neurological diseases like ALS and Alzheimer's using iPS cell technology and regenerative medicine based on Keio University research.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Dec 31, 2025-993+17.31%
Dec 31, 2024-846-425.15%
Dec 31, 2023260-166.34%
Dec 31, 2022-392+71.58%
Dec 31, 2021-229-15.67%
Dec 31, 2020-271+5.87%
Dec 31, 2019-256+0.00%
Oct 31, 2019-256+155.18%
Dec 31, 2018-100

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)